News

Adverse drug events (ADEs) associated with subcutaneous treprostinil use for the treatment of pulmonary arterial hypertension (PAH) were found not to be associated with a higher mortality risk, except for ADEs involving gastrointestinal side effects, which may indicate that the PAH patient population can be divided into subgroups that respond differently…

Icagen and Omdana Therapeutics are teaming up to develop treatments for pulmonary hypertension (PH) and other vascular remodeling diseases, and tissue disorders. At the heart of the collaboration will be a joint treatment discovery team. Omdana develops treatments for PH, whose hallmark is high blood pressure in the lung’s blood…

Johnson & Johnson has completed its acquisition of Actelion, a company that develops pulmonary hypertension therapies, six months after the deal was announced in January. Actelion is now part of J&J’s Janssen Pharmaceuticals subsidiary, according to a news release. Janssen pledged to maintain the leadership position that Actelion built in…

A new Pulmonary Hypertension Association awareness campaign is featuring singer Traci Braxton, who has two sisters with related diseases. The public service ads, an extension of a previous awareness effort, are in print, online, and on radio and television. One target will be commuters going in and out of Amtrak’s Northeast…

https://www.youtube.com/watch?v=ie774xv413A   In this video from GSK, the chairman of the Pulmonary Hypertension Association in the U.K., Iain Armstrong, talks about what pulmonary hypertension (PH) is and how it affects those living with the disease. MORE: Can pulmonary hypertension be prevented? Armstrong explains that the disease affects…

Balloon pulmonary angioplasty, a procedure to widen narrowed lung blood vessels, was still benefitting patients with chronic thromboembolic pulmonary hypertension (CTEPH) six months after doctors performed it, a Japanese study found. The procedure increased patients’ cardiac output, or amount of the blood the heart is pumping, and exercise capacity, researchers said.

Stacie is a 27-year-old who loves the outdoors. Her journey with pulmonary hypertension began when she was an infant: at just 10 months old, she had double pneumonia. Although she recovered, she became sick again a month later. After visiting an on-call doctor who happened to be a heart specialist, her family…

A subcutaneous infusion of Remodulin (treprostinil) was an effective and tolerable treatment against severe pulmonary hypertension associated with chronic kidney disease in a patient on hemodialysis, according to a case report. The case study “Subcutaneous treprostinil was effective and tolerable in a patient with severe pulmonary hypertension associated with…

Early renal denervation (RDN) treatment improved pulmonary arterial hypertension (PAH) in a rat model, a new study from China showed. The study titled, “Effects of renal denervation on monocrotaline induced pulmonary remodeling,” was published in the journal Oncotarget. Despite the progress achieved with oral therapies over the last two decades, the prognosis…

Scientists have long known that people with scleroderma are at increased risk of developing pulmonary arterial hypertension. But many with scleroderma whom doctors suspect of having PAH are not receiving optimal screening for the respiratory condition, a study concludes. Nor are enough scleroderma patients suspected of having pulmonary hypertension being referred for tests that…

MannKind Corporation, which is developing the pulmonary arterial hypertension (PAH) therapy Treprostinil Technosphere, has retained the biopharmaceutical financing specialist Locust Walk to help it raise capital for Treprostinil and other projects. Locust Walk lines up investors and strategic partners for companies like MannKind, which also wants to use its Technosphere technology to develop…

Researchers implanted a long-term, intravenous therapy-delivery system consisting of internal pumps and catheters in 60 pulmonary arterial hypertension (PAH) patients, according to a clinical trial. The IV infusion system, developed by Medtronic, delivers Remodulin (treprostinil). The research team said the system should be easier to use than current therapy-delivery methods.